The notices it replaced
- Reissues: RFA-HL-20-028 Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
Replaced by RFA-HL-26-020.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,126,905 in first-year total cost, median $381,000.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-O (O2)]3
Most frequent institutions
- UNIVERSITY OF CINCINNATI1
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
- UNIVERSITY OF VERMONT & ST AGRIC COLLEGE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Preclinical Optimization and Design for Manufacturability of Immunoregulatory TEVGs1R33HL177449-01 | TZENG, EDITHVORP, DAVID ALAN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $344,056 | ZHL1 |
| 2024 | Continued Clinical Development of a Novel Pleural and Tracheal Sealant1R33HL171782-01 | WEISS, DANIEL J | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $381,000 | ZHL1 |
| 2023 | Using vortical airflow to pressurize the upper airway without a tight seal during CPAP therapy1R33HL161814-01A1 | OREN, LIRAN | UNIVERSITY OF CINCINNATI, OH | $401,849 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.